Skip to main content
. 2022 Apr 9;16(3):691–701. doi: 10.1007/s12072-022-10332-9

Table 1.

Baseline characteristics of cirrhotic participants

Characteristics Total (n = 553) C-cirrhosis (n = 388) D-cirrhosis (n = 165) p value
Age, years 54 (45–61) 53 (45–64) 54 (44–60) 0.184
Sex, male 374 (67.63) 261 (67.27) 113 (68.48) 0.843
Body mass index 24 (22.2–26.0) 23.8 (22.0–25.4) 24 (22.5–26.3) 0.059
Overweight 223 (40.33) 157 (40.46) 66 (40.0) 0.999
Etiology
 HBV 466 (84.27) 338 (87.11) 128 (77.58) 0.007
 HCV 36 (6.69) 22 (5.9) 14 (8.48) 0.267
 Alcoholic 40 (7.45) 24 (6.45) 16 (9.7) 0.213
 NAFLD 17 (3.07) 15 (3.87) 2 (1.21) 0.113
 AIH/PBC/PSC 13 (2.42) 9 (2.41) 4 (2.42) 0.999
 Others 23 (4.16) 14 (3.61) 9 (5.45) 0.353
Chronic hepatitis B
 HBeAg positive 99 (20.54) 79 (23.58) 20 (13.61) 0.014
 HBV DNA positive 122 (22.18) 87 (22.48) 35 (21.47) 0.823
 Antiviral therapy 351 (63.47) 273 (70.36) 78 (47.27)  < 0.001
Comorbidities
 Any 112 (20.25) 73 (18.81) 39 (23.64) 0.205
 Hypertension 70 (13.97) 47 (13.82) 23 (14.29) 0.891
 Diabetes 54 (10.82) 35 (10.36) 19 (11.8) 0.645
 Arrhythmia 13 (2.78) 9 (2.69) 4 (3.03) 0.765
 Asthma 1 (0.2) 1 (0.3) 0 (0) 0.514
 CAD 10 (2.01) 6 (1.79) 4 (2.48) 0.734
Liver function
 ALT, U/L 27.0 (18.0–39.0) 26.0 (18.0–37.2) 28.3 (19.9–45) 0.104
 AST, U/L 27.8 (21.4–39.0) 27.0 (21.0–35.0) 31.0 (23.0–55.4)  < 0.001
 Albumin, g/L 45.3 (41.0–48.2) 45.7 (42.3–48.5) 43.0 (34.8–47.2)  < 0.001
 TBIL, μmol/L 18.3 (13.7–25.1) 16.8 (12.8–22.4) 23.4 (16.0–35.1)  < 0.001
 DBIL, μmol/L 4.4 (2.9–7.5) 3.8 (2.6–6.2) 6.7 (3.8–11.5)  < 0.001
 GGT, U/L 30.0 (18.8–55) 28.0 (19.0–48) 35.0 (20.7–68.0) 0.014
 ALP, U/L 77.6 (63.0–98.5) 75.4 (63.0–92.0) 89.0 (64.0–113.0) 0.002
Child–Pugh  < 0.001
 A 490 (88.61) 377 (97.16) 113 (68.48)
 B + C 63 (11.39) 11 (2.84) 52 (31.52)

Data are displayed as median (interquartile range) and n (%). AIH, autoimmune hepatitis; ALT, alanine aminotransferase; ALP, alkaline phosphatase; AST, aspartate aminotransferase; CAD, Coronary artery disease; C-cirrhosis, compensated cirrhosis; DBIL, direct bilirubin; D-cirrhosis, decompensated cirrhosis; GGT, γ-glutamyl transpeptidase; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; HCV, hepatitis C virus; NAFLD, nonalcoholic fatty liver disease; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis; TBIL, total bilirubin